Sudarshan Pharma Secures Approval for Project Relocation and Boosts Manufacturing Capacit

Sudarshan Pharma Industries Limited (SPIL) has received approval to relocate its Vitamin B6 and B1 projects from Maharashtra to Gujarat, with an extended production timeline to December 31, 2027. Additionally, SPIL has invested Rs. 25.50 crore in acquiring a fully operational API manufacturing facility in Telangana from Srigen Lifesciences Private Limited. This strategic move is expected to enhance production capacity, expand product portfolio, and accelerate market responsiveness.